Biomarkers for Targeted Therapies and Immune Checkpoint Inhibitors in Advanced NSCLC

被引：0
|
作者：
Wang, Jie [1 ]
机构：
[1] Chinese Acad Med Sci, Canc Hosp, Thorac Med Oncol, Beijing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
Immune checkpoint inhibitors; biomarker; dynamic change; Targeted Therapies;
D O I：
10.1016/j.jtho.2016.11.142
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MTE09.01
引用
收藏
页码：S157 / S158
页数：2
相关论文
共 50 条
  • [21] Biomarkers for immune checkpoint inhibitors in advanced nonsmall cell lung cancer
    Pirker, Robert
    CURRENT OPINION IN ONCOLOGY, 2019, 31 (01) : 24 - 28
  • [22] Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC
    Miyawaki, Taichi
    Naito, Tateaki
    Kodama, Akihro
    Nishioka, Naoya
    Miyawaki, Eriko
    Mamesaya, Nobuaki
    Kawamura, Takahisa
    Kobayashi, Haruki
    Omori, Shota
    Wakuda, Kazushige
    Ono, Akira
    Kenmotsu, Hirotsugu
    Murakami, Haruyasu
    Notsu, Akifumi
    Mori, Keita
    Harada, Hideyuki
    Endo, Masahiro
    Takahashi, Kazuhisa
    Takahashi, Toshiaki
    JTO CLINICAL AND RESEARCH REPORTS, 2020, 1 (02):
  • [23] Circulating biomarkers as predictors of response to immune checkpoint inhibitors in NSCLC: Are we on the right path?
    Spagnolo, Calogera Claudia
    Pepe, Francesco
    Ciappina, Giuliana
    Nucera, Francesco
    Ruggeri, Paolo
    Squeri, Andrea
    Speranza, Desiree
    Silvestris, Nicola
    Malapelle, Umberto
    Santarpia, Mariacarmela
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 197
  • [24] Biomarkers for immune checkpoint inhibitors Reply
    Calabro, Luana
    Maio, Michele
    LANCET ONCOLOGY, 2014, 15 (01): : E1 - E2
  • [25] Biomarkers for immune Checkpoint inhibitors in Melanoma
    Kitano, Shigehisa
    Nakayama, Takayuki
    Yamashita, Makiko
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [26] Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations—Chances and Challenges
    Marvin Kuske
    Ricarda Rauschenberg
    Marlene Garzarolli
    Michelle Meredyth-Stewart
    Stefan Beissert
    Esther G. C. Troost
    Oliva Isabella Claudia Glitza
    Friedegund Meier
    American Journal of Clinical Dermatology, 2018, 19 : 529 - 541
  • [27] Prediction of response to targeted and immune checkpoint therapies
    Blair, Edward D.
    Kaufmann, Martina
    Keppens, Mieke
    PERSONALIZED MEDICINE, 2018, 15 (01) : 45 - 56
  • [28] Targeted Therapies Combined With Immune Checkpoint Therapy
    Prieto, Peter A.
    Reuben, Alexandre
    Cooper, Zachary A.
    Wargo, Jennifer A.
    CANCER JOURNAL, 2016, 22 (02): : 138 - 146
  • [29] Targeted therapies in the treatment of advanced/metastatic NSCLC
    Pallis, A. G.
    Serfass, L.
    Dziadziusko, R.
    van Meerbeeck, J. P.
    Fennell, D.
    Lacombe, D.
    Welch, J.
    Gridelli, C.
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (14) : 2473 - 2487
  • [30] Efficacy and Safety of Immune-Checkpoint Inhibitors in Advanced NSCLC Patients with Rare Mutation after Developing Targeted Therapy Resistance
    Zhang, W.
    Li, Y.
    Jiang, H.
    Wang, D.
    Liu, B.
    Qian, F.
    Zhang, B.
    Zhang, Y.
    Li, R.
    Ma, W.
    Han, B.
    Lou, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S601 - S601
12345